The effects and efficacy of Leqselvi (Deuruxolitinib)

Leqselvi (Deuruxolitinib) is a JAK (Janus kinase) inhibitor that plays an important role in the treatment of severe hair loss (alopecia areata) in adults. Alopecia areata is an autoimmune disease in which the immune system mistakenly attacks hair follicles, causing hair loss. Leqselvi is a tablet that is taken twice daily to help hair growth in the affected area. Deuruxolitinib, the main component of Leqselvi, acts as a JAK kinase inhibitor and affects inflammation and immune responses by regulating signaling pathways, thereby improving the symptoms of patients with alopecia areata.

The JAK enzyme is a protein that sends signals to cause inflammation and immune responses, which can lead to alopecia areata and other autoimmune diseases. JAKs mediate signaling of many cytokines and growth factors important for hematopoiesis and immune function. JAK signaling involves the recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus, resulting in the regulation of gene expression.

Deuruxolitinib binds to JAK1, JAK2 and TYK2 and can effectively inhibit the activity of these JAK enzymes. Although the exact relationship between JAK enzyme inhibition and therapeutic effect is still unclear, Leqselvi's mechanism of action is believed to prevent overactive immune responses and reduce inflammation of hair follicles, thereby promoting healthier hair follicle growth and thereby promoting hair regeneration.

Leqselvi, an oral tablet taken twice daily, can help restore hair growth in affected areas and improve symptoms of alopecia areata in patients. By modulating the activity of JAK kinase, Leqselvi is expected to become an effective treatment option for patients with severe alopecia areata, providing them with new hope and the opportunity to improve their quality of life.